Clinical and biochemical investigation of male patients exhibiting membranous cytoplasmic bodies in biopsied kidney tissues; a pitfall in diagnosis of Fabry disease
- PMID: 26312237
- PMCID: PMC4544560
- DOI: 10.12860/jnp.2015.17
Clinical and biochemical investigation of male patients exhibiting membranous cytoplasmic bodies in biopsied kidney tissues; a pitfall in diagnosis of Fabry disease
Abstract
Background: The existence of membranous cytoplasmic bodies in biopsied kidney tissues is one of the important findings when considering Fabry disease as the first choice diagnosis. However, there are possible acquired lysosomal diseases associated with pharmacological toxicity, although less attention has been paid to them.
Case presentation: We experienced 3 male patients presenting with proteinuria and specific pathological changes strongly suggesting Fabry disease. We sought detailed clinical and biochemical information to avoid a wrong diagnosis. The patients were examined clinically and pathologically, and plasma α-galactosidase A (GLA) activity and the globotriaosylsphingosine (lyso-Gb3) concentrations were measured. Electron microscopic examination revealed numerous membranous inclusion bodies in podocytes, and biochemical analysis revealed normal GLA activity and a normal lyso-Gb3 level in plasma, showing that they did not have Fabry disease. They suffered from hyperlipidemia, myeloma, or lupus nephritis. They had received pitavastatin calcium, clarithromycin, loxoprofen and/or prednisolone, and there was no medication history of cationic amphiphilic drugs.
Conclusions: In this case series, the etiology of the inclusions was not clarified. However, these cases indicate that careful attention should be paid on diagnosis of patients exhibiting inclusion bodies in kidney cells, and it is important to confirm their past and present illnesses, and medication history as well as to measure the GLA activity and lyso-Gb3 level.
Keywords: Acquired lysosomal disease; Fabry disease; Globotriaosylsphingosine; Inclusion body; α-Galactosidase A.
Similar articles
-
Plasma mutant α-galactosidase A protein and globotriaosylsphingosine level in Fabry disease.Mol Genet Metab Rep. 2014 Aug 2;1:288-298. doi: 10.1016/j.ymgmr.2014.07.005. eCollection 2014. Mol Genet Metab Rep. 2014. PMID: 27896103 Free PMC article.
-
Does administration of hydroxychloroquine/amiodarone accelerate accumulation of globotriaosylceramide and globotriaosylsphingosine in Fabry mice?Mol Genet Metab Rep. 2021 May 29;28:100773. doi: 10.1016/j.ymgmr.2021.100773. eCollection 2021 Sep. Mol Genet Metab Rep. 2021. PMID: 34136356 Free PMC article.
-
Plasma globotriaosylsphingosine as a biomarker of Fabry disease.Mol Genet Metab. 2010 Jul;100(3):257-61. doi: 10.1016/j.ymgme.2010.03.020. Epub 2010 Apr 1. Mol Genet Metab. 2010. PMID: 20409739
-
Biomarkers for Diagnosing and Staging of Fabry Disease.Curr Med Chem. 2018;25(13):1530-1537. doi: 10.2174/0929867324666170616102112. Curr Med Chem. 2018. PMID: 28618999 Review.
-
Migalastat: A Review in Fabry Disease.Drugs. 2019 Apr;79(5):543-554. doi: 10.1007/s40265-019-01090-4. Drugs. 2019. PMID: 30875019 Free PMC article. Review.
Cited by
-
High-risk screening for Fabry disease in hemodialysis patients in Chiba Prefecture, Japan.Clin Exp Nephrol. 2023 Mar;27(3):288-294. doi: 10.1007/s10157-022-02295-w. Epub 2022 Dec 27. Clin Exp Nephrol. 2023. PMID: 36574104
-
Ultrastructural deposits appearing as "zebra bodies" in renal biopsy: Fabry disease?- comparative case reports.BMC Nephrol. 2017 May 12;18(1):157. doi: 10.1186/s12882-017-0571-0. BMC Nephrol. 2017. PMID: 28499424 Free PMC article.
-
Zebra Bodies in the Kidney: Is it a Pathognomonic Finding of Fabry Disease?Indian J Nephrol. 2025 Mar-Apr;35(2):298-301. doi: 10.25259/ijn_392_23. Epub 2024 Jun 4. Indian J Nephrol. 2025. PMID: 40060053 Free PMC article.
References
-
- Desnick RJ, Ioannou YA, Eng CM. α-Galactosidase A deficiency: Fabry disease. In: Scriver CR, Sly WA, Beaudet A L, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York: McGraw-Hill; 2001. p. 3733-74.
-
- Rombach SM, Dekker N, Bouwman MG, Linthorst GE, Zwinderman AH, Wijburg FA. et al. Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease. Biochim Biophys Acta. 2010;1802(9):741–8. - PubMed
-
- van Breemen MJ, Rombach SM, Dekker N, Poorthuis BJ, Linthorst GE, Zwinderman AH. et al. Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy. Biochim Biophys Acta. 2011;1812(1):70–6. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous